Argenica Therapeutics Limited (ASX: AGN) - Share Price
- Current share price for AGN : $0.095
Argenica Therapeutics Limited (AGN) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a Company engaged in research and development of a neuroprotective therapeutic drug. Its neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).
AGN General Information +
| ASX Code | AGN |
| Website | http://www.argenica.com.au |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 12 |
| AGN Share Price | $0.095 |
| Day High | $0.000 |
| Day Low | $0.000 |
| Last Close | $0.095 |
| AGN Share Price Movement | - ( No change ) |
Prices as at 16:40, 6 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Argenica Therapeutics Limited (AGN) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Argenica Therapeutics Limited (AGN) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Argenica Therapeutics Limited (AGN) price-sensitive announcements
AGN - Quarterly Activities/Appendix 4C Cash Flow Report
Argenica Therapeutics Limited (ASX: AGN) reported quarterly activities and Appendix 4C cas
Argenica Therapeutics Limited (AGN)
30 Oct 2026 | 9:10 AM
30 Oct 2026 | 9:10 AM
AGN - New Mechanism Findings Offer Insights Into Phase 2 Signal
Argenica Therapeutics announced new pharmacology findings supporting the multi-target neur
Argenica Therapeutics Limited (AGN)
20 Oct 2026 | 8:43 AM
20 Oct 2026 | 8:43 AM
AGN - Appendix 4E & Annual Report to 30 June 2026
The Appendix 4E and Annual Report of Argenica Therapeutics Limited for the financial year
Argenica Therapeutics Limited (AGN)
26 Aug 2026 | 4:29 PM
26 Aug 2026 | 4:29 PM
AGN - Quarterly Activities/Appendix 4C Cash Flow Report
Argenica Therapeutics Limited, an Australian biotechnology company, is focused on developi
Argenica Therapeutics Limited (AGN)
24 Jul 2026 | 9:18 AM
24 Jul 2026 | 9:18 AM
Argenica Therapeutics Limited (AGN) Recent ASX Announcements
AGN Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$1.37 | -$1.10 | -81.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$7.17 | -$5.60 | 6.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$5.48 | -$5.30 | -4.00% | 0.00 | 0.00 | 0.00% | 0.0% |
AGN Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Argenica Therapeutics Limited (AGN) | $12M | -0.8114 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Clarity Pharmaceuticals Ltd (CU6) | $597M | 0.4454 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,946M | -0.7857 | 0.2462 | 0.9655 | 99.8711 | 80.1379 | 40.7719 | 0.00% | 1.42% | 1.68% |
AGN Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 2.07 | 0.00 |
| Market | 0.30 | 13.40 | 1.03 | 0.75 |
| Sector | 0.78 | 33.40 | 2.19 | 2.23 |
AGN Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Liz Dallimore | Chief Executive Officer, Managing Director | 4 Apr 2022 |
| Dr Jeannie(Jeannette) Joughin | Non-Executive Director | 2 Dec 2024 |
| Dr Mark Etherton | Non-Executive Director | 17 Sep 2024 |
Argenica Therapeutics Limited (AGN) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 29 Sep 2026 | JOUGHIN, Jeannie(Jeannette) | Buy | Direct Shares | 142,643 | $0.140 | $19,970.020 |
| 14 Aug 2024 | ANGUS, Dianne | Issued | Options | 500,000 | $0.275 | $137,727.000 |
| 8 Aug 2024 | BUDGE, Terrence (Terry) | Cancelled | Options | 181,818 | $1.000 | $181,818.000 |
See all changes in directors' interest & trades for Argenica Therapeutics Limited (AGN) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
AGN Management
| Name | Position |
|---|---|
| Emma Waldon | Chief Financial Officer,Company Secretary |
AGN Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Argenica Therapeutics Limited (AGN). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 7,835,976 (6.10%) | Neil Delroy |
AGN Calendar of Events
| Date | Event |
|---|---|
| 25 August 2027 | Report (Annual) |
| 25 August 2027 | Report (Prelim) |
| 10 February 2027 | Report (Interim) |
| 19 November 2026 | AGM |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
